Focus on Nintedanib in NSCLC and Other Tumors

Nintedanib is a new triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and fibroblast growth factor receptors. Evidence about its efficacy in addition to second-line chemothe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Med (Lausanne)
Asıl Yazarlar: Manzo, Anna, Carillio, Guido, Montanino, Agnese, Costanzo, Raffaele, Sandomenico, Claudia, Rocco, Gaetano, Morabito, Alessandro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2016
Konular:
Medicine
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5165233/
https://ncbi.nlm.nih.gov/pubmed/28066768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2016.00068
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller